Not finding it? Sign in to also search OpenAlex live.
-
Dysfunctional CD4 T cells in an oncovirus-specific TCR-transgenic in vivo model2025 Nature Communications article Immunology and Microbiology T-cell and B-cell Immunology Open access
Felicia S. Spitzer, Marcel G M Camps, Cedrik Michael Britten, Sandra A. Vloemans, Hester J.T. van Zeeburg, Cornelis J.M. Melief, +2 more
0citations -
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma2024 New England Journal of Medicine article Medicine Cutaneous Melanoma Detection and Management Open access
Christian U Blank, Minke W Lucas, Richard A. Scolyer, Bart A. van de Wiel, Alexander Maxwell Menzies, Marta López‐Yurda, +62 more
538citations -
Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem2021 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access
Kikkie Poels, Suzanne I.M. Neppelenbroek, Marie José Kersten, M. Louisa Antoni, Esther Lutgens, Tom T. P. Seijkens
61citations -
Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study2020 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 1 patent
Els M.E. Verdegaal, Monique K. van der Kooij, Marten Visser, Caroline E. van der Minne, Linda de Bruin, Pauline Meij, +8 more
29citations -
Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up2022 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access
Eva Oswald, Daniel Bug, Anne Grote, Kanstantsin Lashuk, Nassim Bouteldja, Dorothée Lenhard, +10 more
14citations -
LBA57 Two-year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma2025 Annals of Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
M.W. Lucas, Alexander Maxwell Menzies, Petros Dimitriadis, S C M A Wijnen, Marta López‐Yurda, Richard A. Scolyer, +13 more
12citations -
52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)2022 Annals of Oncology article Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access
A. Vogel, S. Boeck, O. Waidmann, Michael Bitzer, P. Wenzel, S. Belle, +13 more
9citations -
Searching for Monogenic Autoimmune Etiology in Patients With Type 1 Diabetes Onset Before 30 Months of Age2025 The Journal of Clinical Endocrinology & Metabolism article Biochemistry, Genetics and Molecular Biology Diabetes and associated disorders Open access
Laura Saso-Jiménez, Inés Urrutia, Begoña Calvo Martínez, José Ramón Bilbao, Ana Lucía Gómez-Gila, Isabel Leiva Gea, +4 more
3citations -
Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis and biomarker study
Charlotte I. Stroes, Sybren L. Meijer, Geert‐Jan Creemers, Gerrit K. J. Hooijer, Nadia Haj Mohammad, Maartje Los, +6 more
3citations -
1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort
Rieke Nila Fischer, Julie George, Andreas Hans Scheel, Hans Anton Schloesser, Peter Brossart, W. Engel-Riedel, +14 more
1citations